
Postdoctoral fellow @fredhutch co-advised by @GhajarLab and Dr. Stanley Riddell. Studying how the immune system regulates breast cancer dormancy and metastasis.
Joined February 2020
- Tweets111
- Following403
- Followers236
- Likes414
Pinned Tweet
I am so excited to finally see my PhD work out in @CD_AACR. We were able to investigate the immunotherapeutic benefit of reprogramming cancer cells into antigen presenting cells and were surprised by the dramatic responses we observed. A brief thread on our findings:
Now online in @CD_AACR: Reprogramming Cancer into Antigen Presenting Cells as a Novel #Immunotherapy - by @mileslinde @majetilab and colleagues @StanfordMed aacrjournals.org/cancerdisco…
Miles Linde retweeted
c-Jun overexpression fails to prevent CAR T cell exhaustion in tumors, but PD-L1 blockade restores c-Jun levels and CAR T cell activity @SciImmunology
science.org/doi/10.1126/scii… @fredhutch
Miles Linde retweeted
Now online in @CD_AACR: DNMT3A R882H Is Not Required for Disease Maintenance in Primary Human AML, but Is Associated With Increased Leukemia Stem Cell Frequency - by @ThomasKoehnke, @DKarigane
@majetilab and colleagues doi.org/10.1158/2159-8290.CD… @StanfordMed
What a blast to see @RaviMajetiMD at @fredhutch giving the TST seminar this afternoon. Exciting recent work from close @majetilab friends @ThomasKoehnke, @amycfanphd, and Daiki on clonal competition in AML and DNMT3A’s role in leukemia initiation. Proud to be a Majeti lab alum!
Miles Linde retweeted
Our work on ASXL1 mutations in clonal hematopoiesis and myeloid malignancies - @ThomasKoehnke
@BCD_AACR
#BloodCancer #Cancer #Leukemia #MyeloidMalignancies #OncoDaily #Oncology #TothovaLab
oncodaily.com/36016.html
Miles Linde retweeted
Excited to share our work on ASXL1 mutations in clonal hematopoiesis and myeloid malignancies, out in Blood Cancer Discovery @BCD_AACR doi.org/10.1158/2643-3230.BC…
Miles Linde retweeted
Read this week's Cancer Discovery #ResearchWatch:
Relative Scarcity of Disseminated Tumor Cells Enables Immune Evasion, summarizing the work of Erica T. Goddard, @mileslinde, Stanley R. Riddell, @GhajarLab et al.
bit.ly/42pyPn6
@fredhutch
Miles Linde retweeted
While dormant disseminated tumor cells (DTCs) downregulate MHC-I, the primarily evade antitumor immunity though “relative scarcity”. More details here 👉 bit.ly/3HoAGim @fredhutch @GhajarLab
Miles Linde retweeted
Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies dlvr.it/T1Clmm
Miles Linde retweeted
Our @GhajarLab and Riddell Lab team up for a study that explains why dormant tumor cells evade immune surveillance, and how this can be overcome towards curative therapy.
This is what #METX aims to achieve more of.
Our latest - in joint collaboration w/ Stan Riddell’s Lab here at the Hutch – reveals a novel mode of immune evasion we call “relative scarcity” that explains why dormant disseminated tumor cells escape surveillance by antigen-directed T cells:
authors.elsevier.com/a/1iOZY…
(1/n)
Miles Linde retweeted
Our latest - in joint collaboration w/ Stan Riddell’s Lab here at the Hutch – reveals a novel mode of immune evasion we call “relative scarcity” that explains why dormant disseminated tumor cells escape surveillance by antigen-directed T cells:
authors.elsevier.com/a/1iOZY…
(1/n)
Disseminated tumor cells (DTCs) -the root of metastatic relapse- evade T cell immunosurveillance at least in part through infrequent interactions with antigen specific T cells. This paucity of interactions can be overcome with T cell immunotherapy. authors.elsevier.com/c/1iOZY…
Finally, go check out @GhajarLab’s thread for a thorough discussion on our findings (and even more thank yous to collaborators and funding)!
1
2
112
Miles Linde retweeted
IDH1-mutant preleukemic #hematopoietic #stemcells can be eliminated by inhibition of oxidative phosphorylation, by Niklas Landberg, @majetilab et al.
bit.ly/48dWQzA
@StanfordMed #LeuSM
Miles Linde retweeted
In the May issue—
Reprogramming Cancer into Antigen Presenting Cells as a Novel #Immunotherapy, by @mileslinde, @majetilab et al.
https://teapaw.org/t.co/4s4W2lpM2W
@StanfordMed
Miles Linde retweeted
Researchers have found a way to convert cancer cells into harmless antigen-presenting cells, allowing T-cells to find and attack cancer, a new Stanford study suggests. stanforddaily.com/2023/03/14…
Thank you to @ACIR_org for highlighting our work! A clear and concise, yet thoughtful and comprehensive description of our studies complemented by a phenomenal graphical depictions!
Reprogramming tumors to present themselves to the immune system.
Read our digest here 👉 https://teapaw.org/t.co/rD1RZ3GDre @stanfordMed @majetilab @mileslinde
A particular thank you to @Wouterville for the writing and Lauren Hitchings for the graphical abstract!
2
120























